Condition
B Cell Malignancy
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Early P 1 (1)
P 1 (3)
Trial Status
Unknown2
Suspended1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06662227Early Phase 1Suspended
Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors
NCT03953599Phase 1CompletedPrimary
CD19-Synthetic T Cell Antigen Receptor(STAR)-T in B-cell Malignancies Patients
NCT04384393Phase 1UnknownPrimary
Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies
NCT04601181Phase 1UnknownPrimary
Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies
Showing all 4 trials